PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/735,594		
Filing Date	December 12, 2003		
First Named Inventor	Charles L. Brooks		
Art Unit	To Be Determined		
Examiner Name	To Be Determined		
Attorney Docket Number	18525/04051		

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
MIT		^{US-} 6,429,186	08-06-2002	Fuh et al.	
MT.		^{US-} 2001/0036662	11-01-2001	Walker	
		US-			
-		US-			
	<u> </u>	US-			
		US·			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Cite Initials* No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	۲'
						L
	ļ					┡
-						┝
		120000000000000000000000000000000000000				T
						T

Examiner Signature	The	75/	Date Considered	10.08.04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ADBHOOLE for form 1449/PTO				Complete if Known		
1400				Application Number	10/735,594	
INF	ORMATION	DIS	CLOSURE	Filing Date	December 12, 2003	
STATEMENT BY APPLICANT (Use as many sheets as necessary)		First Named Inventor	Charles L. Brooks			
		Art Unit	To Be Determined			
	(Ose as many site	1012 82 11	ecessary)	Examiner Name	To Be Determined	
Sheet	2	of	3	Attorney Docket Number	18525/04051	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		KUNKEL, T.A., "Rapid and officient site-specific mutagenesis without phenotypic selection", Proc. Natl. Acad. Sci. USA, January 1985, Volume 82, Pages 488-492.	
Mrt.		KUNKEL et al., "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection", Methods in Enzymology, Volume 154, Pages 367-382.	
]		DUDA et al., "Human growth hormone site 2 lactogenic activity requires a distant tyrosine164", <u>FEBS Letters</u> , 1999, Volume 449, Pages 120-124.	
		KUNKEL et al., "Efficient Site-Directed Mutagenesis using Uracil-Containing DNA", Methods in Enzymology, 1991, Volume 204, Pages 125-139.	
		PETERSON et al., "Identification of a Motif Associated with the Lactogenic Actions of Human Growth Hormone", <u>The Journal of Biological Chemistry</u> , 1997, Volume 272, Issue 34, Pages 21444-21448.	
		PETERSON et al., "Expression, Folding, and Characterization of Small Proteins with Increasing Disulfide Complexity by a pT7-7-Derived Phagemid", <u>Protein Expression and Purification</u> , 1999, Volume 15, Pages 16-23.	
		MUNSON et al., "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems", Analytical Biochemistry, 1980, Volume 107, Pages 220-239.	
		CHANTALAT et al., "The Crystal Structure of Wild-Type Growth Hormone at 2.5 A Resolution", <u>Protein and Peptide Letters</u> , 1995, Volume 2, Number 2, Pages 333-340.	
		SOMERS et al., "The X-ray structure of a growth hormone-prolactin receptor complex", Letters To Nature, December 1, 1994, Volume 372, Pages 478-481.	
m.T.		DUDA et al., "Identification of Residues Outside the Two Binding Sites That Are Critical for Activation of the Lactyogenic Activity of Human Growth Hormone", The Journal of Biological Chemistry, 2003, Volume 278, Number 25, Pages 22734-22739.	

Examiner		Date	
Signature 4	The la	Considered	10.03.04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with new communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/735,594 **INFORMATION DISCLOSURE Filing Date** December 12, 2003 STATEMENT BY APPLICANT First Named Inventor Charles L. Brooks Art Unit To Be Determined (Use as many sheets as necessary) **Examiner Name** To Be Determined Attorney Docket Number Sheet 18525/04051 13 of 3

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
N.T.	•	KEELER et al., "The Tertiary Structure and Backbone Dynamics of Human Prolactin", <u>Journal of Molecular Biology</u> , 2003, Volume 328, Pages 1105-1121.	
И.Т. М.Т.		ELKINS et al., "Ternary complex between placental lactogen and the extracellular domain of the prolactin receptor", Nature Structural Biology, Volume 7, Number 9, Pages 808-815.	
		MATERA et al., "Prolactin is an autocrine growth factor for the Hurkat human T-leukemic cell line", <u>Journal of Neuroimmunology</u> , 1997, Volume 79, Pages 12-21.	
M.T.		BERNICHTEIN et al., "Development of Pure Prolactin Receptor Antagonists", <u>The</u> <u>Journal of Biological Chemistry</u> , 2003, Volume 278, Number 38, Pages 35988-35999.	
M.T. M.T. M.T. M.T. M.T.		BOLE-FEYSOT et al., "Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice", <u>Endocrine Reviews</u> , 1998, Volume 19, Number 3, Pages 225-268.	
M.T.		CLEVENGER et al., "Prolactin receptor signal transuction in cells of the immune system", <u>Journal of Endocrinology</u> , 1998, Volume 157, Pages 187-197.	
M.T.		WELLS, James A., "Binding in the growth hormone receptor complex", <u>Proc.</u> Natl. Acad. Sci. USA, January 1996, Volume 93, Pages 1-6.	
		·	
		-	

Examiner Signature Co	ate onsidered 10.08.04
-----------------------	---------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form wip next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). This collection is information is required by 37 CPR 1.36. The information is equired by a complete application of the use of the complete application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.